CR20210368A - Combinación de dextrometorfano y bupropión para el tratamiento de depresión - Google Patents

Combinación de dextrometorfano y bupropión para el tratamiento de depresión

Info

Publication number
CR20210368A
CR20210368A CR20210368A CR20210368A CR20210368A CR 20210368 A CR20210368 A CR 20210368A CR 20210368 A CR20210368 A CR 20210368A CR 20210368 A CR20210368 A CR 20210368A CR 20210368 A CR20210368 A CR 20210368A
Authority
CR
Costa Rica
Prior art keywords
bupropion
dextrometorphan
depression
treatment
combination
Prior art date
Application number
CR20210368A
Other languages
English (en)
Inventor
Herriot Tabuteau
Original Assignee
Antecip Bioventures Ii Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Antecip Bioventures Ii Llc filed Critical Antecip Bioventures Ii Llc
Publication of CR20210368A publication Critical patent/CR20210368A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/485—Morphinan derivatives, e.g. morphine, codeine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Emergency Medicine (AREA)
  • Epidemiology (AREA)
  • Psychiatry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Se divulgan las formas de dosificación, sistemas de suministro de fármacos y métodos relacionados con la liberación sostenida de dextrometorfano o efectos terapéuticos mejorados. Típicamente, bupropión o un compuesto relacionado se administra por vía oral a un ser humano a ser tratado con o que es tratado con dextrometorfano.
CR20210368A 2019-01-07 2020-01-07 Combinación de dextrometorfano y bupropión para el tratamiento de depresión CR20210368A (es)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201962789431P 2019-01-07 2019-01-07
US201962789446P 2019-01-07 2019-01-07
US201962789488P 2019-01-07 2019-01-07
US201962789451P 2019-01-07 2019-01-07
PCT/US2020/012612 WO2020146412A1 (en) 2019-01-07 2020-01-07 Combination of dextromethorphan and bupropion for treating depression

Publications (1)

Publication Number Publication Date
CR20210368A true CR20210368A (es) 2021-12-10

Family

ID=71521902

Family Applications (1)

Application Number Title Priority Date Filing Date
CR20210368A CR20210368A (es) 2019-01-07 2020-01-07 Combinación de dextrometorfano y bupropión para el tratamiento de depresión

Country Status (28)

Country Link
EP (2) EP3908270B1 (es)
JP (1) JP2022516361A (es)
KR (2) KR20240169131A (es)
CN (4) CN114712357A (es)
AU (3) AU2020207261B2 (es)
BR (1) BR112020025902A2 (es)
CA (2) CA3223187A1 (es)
CL (1) CL2021001810A1 (es)
CO (1) CO2021008988A2 (es)
CR (1) CR20210368A (es)
DK (1) DK3908270T3 (es)
EC (1) ECSP21051833A (es)
ES (1) ES3051232T3 (es)
FI (1) FI3908270T3 (es)
HR (1) HRP20251402T1 (es)
IL (1) IL284663A (es)
LT (1) LT3908270T (es)
MX (1) MX2021008247A (es)
MY (1) MY201603A (es)
NZ (1) NZ777261A (es)
PE (1) PE20212249A1 (es)
PL (1) PL3908270T3 (es)
PT (1) PT3908270T (es)
RS (1) RS67453B1 (es)
SG (1) SG11202106392RA (es)
SI (1) SI3908270T1 (es)
SM (1) SMT202600055T1 (es)
WO (1) WO2020146412A1 (es)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US12109178B2 (en) 2013-11-05 2024-10-08 Antecip Bioventures Ii Llc Bupropion as a modulator of drug activity
US11433067B2 (en) 2013-11-05 2022-09-06 Antecip Bioventures Ii Llc Bupropion as a modulator of drug activity
US11969421B2 (en) 2013-11-05 2024-04-30 Antecip Bioventures Ii Llc Bupropion as a modulator of drug activity
US12194006B2 (en) 2013-11-05 2025-01-14 Antecip Bioventures Ii Llc Bupropion as a modulator of drug activity
US11534414B2 (en) 2013-11-05 2022-12-27 Antecip Bioventures Ii Llc Bupropion as a modulator of drug activity
US12569479B2 (en) 2016-05-25 2026-03-10 Antecip Bioventures Ii Llc Bupropion as a modulator of drug activity
SG11202106392RA (en) * 2019-01-07 2021-07-29 Antecip Bioventures Ii Llc Combination of dextromethorphan and bupropion for treating depression
US20250073188A1 (en) 2020-06-05 2025-03-06 Antecip Bioventures Ii Llc Compounds and combinations thereof for treating neurological and psychiatric conditions
US12472156B2 (en) 2020-06-05 2025-11-18 Antecip Bioventures Ii Llc Compounds and combinations thereof for treating neurological and psychiatric conditions
US12433884B2 (en) 2020-06-05 2025-10-07 Antecip Bioventures Ii Llc Compounds and combinations thereof for treating neurological and psychiatric conditions
KR20230113787A (ko) 2020-12-01 2023-08-01 안테씨프 바이오벤쳐스 투 엘엘씨 우울증 환자의 자살 위험 감소를 위한 부프로피온 및덱스트로메토르판
CN117693336A (zh) * 2021-07-21 2024-03-12 安泰赛普生物风投二代有限责任公司 抑郁症的治疗
KR20240046749A (ko) * 2021-08-09 2024-04-09 안테씨프 바이오벤쳐스 투 엘엘씨 우울 증상의 관해를 유지하는 방법
CN119212709A (zh) * 2022-05-17 2024-12-27 安泰赛普生物风投二代有限责任公司 抑郁的治疗
US12156914B2 (en) 2022-06-30 2024-12-03 Axsome Therapeutics, Inc. Pharmaceutical compositions comprising bupropion and cysteine
US11717518B1 (en) 2022-06-30 2023-08-08 Antecip Bioventures Ii Llc Bupropion dosage forms with reduced food and alcohol dosing effects
US12036191B1 (en) 2022-06-30 2024-07-16 Antecip Bioventures Ii Llc Treatment of poor metabolizers of dextromethorphan with a combination of bupropion and dextromethorphan
US11730706B1 (en) 2022-07-07 2023-08-22 Antecip Bioventures Ii Llc Treatment of depression in certain patient populations
US11844797B1 (en) 2023-04-20 2023-12-19 Antecip Bioventures Ii Llc Combination of dextromethorphan and bupropion for treating depression
US12194036B2 (en) 2022-07-07 2025-01-14 Antecip Bioventures Ii Llc Combination of dextromethorphan and bupropion for treating depression
WO2025117954A1 (en) * 2023-12-01 2025-06-05 Axsome Therapeutics, Inc. Compounds and combinations thereof for treating depression in patients

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2009525343A (ja) * 2006-02-03 2009-07-09 アバニール・ファーマシューティカルズ 鬱病、不安および神経変性疾患を治療するためのデキストロメトルファンおよびキニジンを含む薬剤組成物
CA2886573C (en) * 2012-10-11 2019-04-02 Stephen Lim Chin Beng Solid dosage form
JP6406713B2 (ja) * 2013-01-30 2018-10-17 ファーモレックス セラピューティクス， インコーポレイテッド 低用量薬剤によるうつ病および他の疾患の処置
US9402843B2 (en) * 2013-11-05 2016-08-02 Antecip Bioventures Ii Llc Compositions and methods of using threohydroxybupropion for therapeutic purposes
US10512643B2 (en) * 2013-11-05 2019-12-24 Antecip Bioventures Ii Llc Compositions and methods for increasing the metabolic lifetime of dextromethorphan and related pharmacodynamic effects
KR102603013B1 (ko) * 2013-11-05 2023-11-15 안테씨프 바이오벤쳐스 투 엘엘씨 부프로피온 또는 관련 화합물과 덱스트로메토르판을 포함하는 조성물 및 방법
EP4166141A1 (en) * 2014-09-14 2023-04-19 Avanir Pharmaceuticals, Inc. Combinations of deuterated dextromethorphan and quinidine for the treatment of agitation and aggression in alzheimer's dementia
KR101931896B1 (ko) * 2014-11-21 2018-12-21 안테씨프 바이오벤쳐스 투 엘엘씨 에리트로히드록시부프로피온을 이용한 약물의 혈장 농도의 조절 방법
SG11202106392RA (en) * 2019-01-07 2021-07-29 Antecip Bioventures Ii Llc Combination of dextromethorphan and bupropion for treating depression

Also Published As

Publication number Publication date
PT3908270T (pt) 2025-11-12
WO2020146412A1 (en) 2020-07-16
CA3126062C (en) 2024-02-06
SMT202600055T1 (it) 2026-03-09
AU2020207261B2 (en) 2023-04-13
PE20212249A1 (es) 2021-11-24
IL284663A (en) 2021-08-31
AU2020207261A1 (en) 2021-07-08
CL2021001810A1 (es) 2022-03-04
CN114712356A (zh) 2022-07-08
PL3908270T3 (pl) 2026-02-16
FI3908270T3 (fi) 2025-11-24
AU2023204348B2 (en) 2025-06-05
JP2022516361A (ja) 2022-02-25
NZ777261A (en) 2024-11-29
RS67453B1 (sr) 2025-12-31
HRP20251402T1 (hr) 2026-01-02
BR112020025902A2 (pt) 2021-07-13
CO2021008988A2 (es) 2021-09-09
CA3223187A1 (en) 2020-07-16
MX2021008247A (es) 2021-08-16
EP3908270B1 (en) 2025-08-27
CN114712357A (zh) 2022-07-08
LT3908270T (lt) 2025-12-10
AU2025203831A1 (en) 2025-06-19
EP4631571A3 (en) 2025-11-26
DK3908270T3 (da) 2025-11-17
SG11202106392RA (en) 2021-07-29
ES3051232T3 (en) 2025-12-26
MY201603A (en) 2024-03-05
KR20240169131A (ko) 2024-12-02
AU2023204348A1 (en) 2023-07-27
KR20210110654A (ko) 2021-09-08
ECSP21051833A (es) 2021-11-18
CA3126062A1 (en) 2020-07-16
EP4631571A2 (en) 2025-10-15
EP3908270A4 (en) 2022-02-16
EP3908270A1 (en) 2021-11-17
CN114712358A (zh) 2022-07-08
CN112437659B (zh) 2022-04-12
CN112437659A (zh) 2021-03-02
SI3908270T1 (sl) 2026-01-30

Similar Documents

Publication Publication Date Title
CL2021001810A1 (es) Combinación de dextrometorfano y bupropión para el tratamiento de depresión
MX393855B (es) Terapia de combinación que comprende un inhibidor de raf y trametinib
MX2024010140A (es) Nuevos metodos.
CL2020002512A1 (es) Tratamiento de la hidradenitis supurativa mediante el uso de inhibidores de jak.
AR134835A2 (es) Tratamiento de la enfermedad de fabry en pacientes no tratados y tratados previamente con ert
MX2021004639A (es) Combinaciones de inhibidores de desmetilasa-1 especifica de lisina (lsd1) para uso en el tratamiento de tumores solidos.
MX384234B (es) Uso de pridopidina para el tratamiento de enfermedad de huntington.
MX2021004546A (es) Composiciones de suministro de farmaco implantables y metodos de uso de las mismas.
MX2019003173A (es) Terapia de combinacion con agonistas de peptido natriuretico tipo c (cnp) de liberacion controlada.
MX390627B (es) Uso de pridopidina para el tratamiento de la disminucion funcional.
PE20142319A1 (es) Tratamiento de esclerosis multiple con combinacion de laquinimod y acetato de glatiramero
AR096892A1 (es) Una combinación farmacéutica para el tratamiento del melanoma
MX2022007908A (es) Combinacion farmaceutica de un oligonucleotido terapeutico que actua sobre hbv y un agonista de tlr7 para el tratamiento de hbv.
BR112012030641A2 (pt) métodos e composições para terapia farmacêutica oral
ZA202000028B (en) Use of vibegron to treat overactive bladder
HK1255584A1 (zh) 使用阿坎酸及d-环丝胺酸的联合疗法
AR101901A1 (es) Tratamiento de enfermedades neurodegenerativas con una combinación de laquinimod y fingolimod
WO2016122288A3 (ko) 베르베논 유도체 및 재관류 치료제를 포함하는 뇌혈관 질환, 동맥경화증 또는 심혈관 질환 치료 또는 예방용 병용 제제
RU2010154623A (ru) Производные 1-аминоалкилциклогексана для лечения расстройств сна
MX2021000714A (es) Preparacion medicinal para uso externo.
MX2021014093A (es) Composiciones y metodos para tratar el mal de alzheimer y la enfermedad de parkinson.
MX385725B (es) Composición farmacéutica que comprende sumatriptán para tratamiento de migraña.
BR112018017167A2 (pt) titulação de cebranopadol
NZ764077A (en) Compositions and methods comprising bupropion or related compounds for sustained delivery of dextromethorphan
MX2021003288A (es) Medicacion para aliviar los sintomas de la neuropatia periferica causada por farmacos anticancerigenos y/o suprimir el inicio de la neuropatia periferica.